Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Day One Biopharmaceuticals Inc shares valued at $426,675 were sold by Blackman Samuel C. on Sep 10 ’24. At $14.22 per share, Blackman Samuel C. sold 30,000 shares. The insider’s holdings dropped to 1,097,535 shares worth approximately $15.88 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Dubow Adam sold 3,202 shares, netting a total of over 44,825 in proceeds. Following the sale of shares at $14.00 each, the insider now holds 26,928 shares.
Before that, York Charles N II had sold 2,633 shares from its account. In a trade valued at $36,860, the COO, CFO AND SECRETARY traded Day One Biopharmaceuticals Inc shares for $14.00 each. Upon closing the transaction, the insider’s holdings decreased to 2,633 shares, worth approximately $3.36 million.
As published in a research note from Needham on October 09, 2024, Day One Biopharmaceuticals Inc [DAWN] has been retained to a Buy and the price target has been revised to $33. Analysts at BofA Securities upgraded the stock from ‘”an Underperform”‘ to ‘”a Buy”‘ outlook in a report released in early August. As of April 24, 2024, Needham has reiterated its “Buy” rating for DAWN. Earlier on April 25, 2023, BofA Securities downgraded its rating. Their new recommendation was “an Underperform” for DAWN stock which previously was a “a Buy”.
Analyzing DAWN Stock Performance
During the last five days, there has been a surge of approximately 0.98%. Over the course of the year, Day One Biopharmaceuticals Inc shares have dropped approximately -0.89%. Shares of the company reached a 52-week high of $18.07 on 05/01/24 and a 52-week low of $11.94 on 06/17/24. A 50-day SMA is recorded $14.17, while a 200-day SMA reached $14.60. Nevertheless, trading volume fell to 1.09 million shares from 0.64 million shares the previous day.
Support And Resistance Levels for Day One Biopharmaceuticals Inc (DAWN)
According to the 24-hour chart, there is a support level at 14.09, which, if violated, would cause prices to drop to 13.70. In the upper region, resistance lies at 14.80. The next price resistance is at 15.12. RSI (Relative Strength Index) is 51.97 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.15, which suggests the price will decrease in the coming days. Percent R is at 50.24%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
